Pfizer outbids Novo Nordisk and takes Metsera for up to $10 billion

What happened

Pfizer agreed in September 2025 to buy Metsera, a young obesity company, for a cash price plus contingent value rights tied to future milestones. In late October, Novo Nordisk made an unsolicited, higher offer. What followed was a short and public fight: improved bids, legal filings over the merger agreement, and statements from both sides about antitrust risk.

In early November Metsera accepted an improved Pfizer offer worth up to about $86 per share, around $10 billion in total if every milestone is paid. Novo stepped back.

What Pfizer gets

Metsera had no approved medicine. Its lead asset, MET-097i, is a GLP-1 receptor agonist engineered to last long enough for monthly dosing. Phase 2 data showed weight loss in line with weekly drugs over the periods studied. The company also brought an amylin analog intended to be combined with it.

Why the board moved

Nothing changed on the stage track: MET-097i was in phase 2 before and after. We mark the signal as up because the programme now has the money and trial capacity of one of the largest drug makers, which changes how fast it can run a phase 3.

• Pfizer had dropped its own oral GLP-1 pill, danuglipron, earlier in 2025.
• Monthly dosing is the main promise; the evidence for long-term tolerability at that interval is still thin.

A deal is a bet, not a result. The molecule still has to work in phase 3.